Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: A randomized, placebo-controlled trial

M. I. Resnick, Claus Roehrborn

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

This randomized, double-blind, placebo-controlled study was conducted to investigate whether alfuzosin 10 mg once daily improves the maximum flow rate (Qmax) and lower urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH) after 1 week and 1 month of treatment. A total of 372 men aged ≥50 years with symptomatic BPH received alfuzosin or placebo for 28 days. Qmax increased significantly from baseline at day 8 with alfuzosin (P<0.001 versus placebo); this improvement was evident within 24 h after the first dose and was maintained at day 29. LUTS improved from baseline with alfuzosin at day 8 (P=0.07 versus placebo) and day 29 (P=0.003 versus placebo). Alfuzosin 10 mg once daily exhibits a rapid onset of action, with improvements in Qmax and LUTS maintained through 1 month of treatment.

Original languageEnglish (US)
Pages (from-to)155-159
Number of pages5
JournalProstate Cancer and Prostatic Diseases
Volume10
Issue number2
DOIs
Publication statusPublished - May 2007

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this